Devyser’s NGS products for monitoring of kidney and stem cell transplant patients receive IVDR approvals
Devyser’s novel test for detecting donor-derived cell-free DNA in blood samples from...
We are excited to announce that we will be attending the cfDNA2023 conference. The meeting promises to provide an excellent overview of the field as presented by key experts and give us the opportunity to discuss scientific and clinical topics with peers from the field. We look forward to learning from and contributing to the conversation at cfDNA2023.
“During early pregnancy, 3-6% of cell-free DNA in the plasma of pregnant women is of fetal origin.”
Dr. Agneta Wikman, M.D., Ph.D, Karolinska University Hospital, Stockholm, Sweden
Choosing and implementing the best screening method for non-invasive fetal-RHD testing. Learn from clinical experts about the shift in today’s screening method for non-invasive fetal-RHD testing. Dr Wikman is a professor and specialist in Transfusion Medicine and Laboratory Medicine.
News | September 06, 2023
Devyser and Thermo Fisher Scientific expand the collaboration for post-transplant NGS products by adding BrazilNews | July 17, 2023
Devyser’s NGS products for monitoring of kidney and stem cell transplant patients receive IVDR approvalsNews | June 29, 2023
Devyser launches two new genetic testing solutions for hereditary cancerDevyser’s novel test for detecting donor-derived cell-free DNA in blood samples from...
Read More
A better patient care is the final objective for Dr. Helena Devos and the team at Sint Jan’s...
Read More
Collaboration and distribution agreement with Thermo Fisher Scientific Thermo Fisher Scientific...
Read More
As a lab manager, you know the importance of streamlining workflows to maximize productivity and...
Read More